Kaempferol Niosomal In Situ Gel Delivers Stronger Ocular Exposure in Dry Eye Disease
Dry eye disease remains a problem of surface inflammation as much as tear instability. In this preclinical study, a kaempferol-loaded niosomal in situ gel was engineered to hold drug at the ocular surface long enough to matter, then release it in a controlled way once exposed to tear fluid. The formulation, called KAE-NIO-ISG, was built to solve two persistent obstacles at once: kaempferol’s poor aqueous solubility and the rapid washout that limits conventional eye drops.
The rationale is straightforward. Dry eye is driven by tear-film hyperosmolarity, epithelial injury, and oxidative stress, which together sustain inflammation and corneal surface damage. Kaempferol is already known for antioxidant and anti-inflammatory activity, but its poor physicochemical properties make it difficult to translate into a useful ophthalmic product. A carrier system that protects the molecule before instillation and prolongs residence after administration offers a plausible route around those barriers.
Niosomes and Gellan Gum Were Combined to Prolong Corneal Residence
Investigators prepared kaempferol niosomes using Tween 80, Span 60, cholesterol, and the thin-film hydration method, then incorporated the vesicles into an ion-sensitive in situ gel matrix. The optimized system produced a mean particle size of 177.27 ± 1.26 nm, a scale that is small enough to support ocular delivery while still allowing vesicular drug carriage. After simulated tear fluid was added, viscosity increased from 27.24 ± 0.49 cp to 238.71 ± 1.75 cp, showing the expected sol-to-gel transition triggered by the ionic environment of the tear film.
That shift is central to the formulation’s design. A low-viscosity solution is easier to instill, but once tear ions are encountered, the gel network thickens and slows drainage. In practical terms, the eye gets a formulation that behaves like a drop at the moment of dosing and more like a depot immediately afterward. For a drug with low corneal permeability, that extra residence time can be the difference between nominal exposure and a meaningful tissue-level effect.
The formulation also demonstrated favorable stability during storage and was well tolerated in irritation testing. Those features matter because ocular delivery systems fail quickly if they sting, destabilize, or phase-separate before reaching the target tissue. The report’s formulation data indicate that the niosomal-gel construct preserved its physical integrity while still responding to physiological conditions at the ocular surface.
Ocular Bioavailability Rose Sharply Compared With Suspension
A major pharmacokinetic finding stood out immediately. The KAE-NIO-ISG system improved ocular bioavailability, with a 23.5-fold increase in corneal area under the curve compared with kaempferol suspension. For an eye-drop platform, this magnitude of change signals more than incremental improvement; it suggests that the formulation is doing the work of retention, protection, and controlled release that simple solutions cannot achieve.
The mechanism is biologically plausible. Niosomes can shelter lipophilic compounds from rapid degradation and help them interact with the mucin-rich ocular surface, while the gel matrix slows precorneal clearance. Together, those features create a longer exposure window for a compound that otherwise clears too quickly to accumulate in the cornea. In drug-delivery terms, the carrier system is not just transporting kaempferol, it is changing the local pharmacokinetic environment around it.
Therapeutic Effect Matched Cyclosporine in the Mouse Model
Efficacy testing used a benzalkonium chloride-induced dry eye mouse model, a well-established platform for reproducing ocular surface damage and tear-film disturbance. In that model, kaempferol improved therapeutic outcomes in a dose-dependent manner, and the high-dose formulation performed at a level equivalent to cyclosporine A after 7 days. For a natural flavonoid to reach parity with a standard immunomodulatory comparator in a short preclinical window is an important result, even before human translation is considered.
The inflammatory logic fits the data. Dry eye involves a cycle of epithelial stress, inflammatory signaling, and further tear-film disruption. An agent with both antioxidant and anti-inflammatory activity can interrupt that cycle on two fronts: by reducing oxidative injury and by dampening the inflammatory cascade that perpetuates surface damage. If a formulation can keep that agent on the ocular surface long enough, the local biology becomes more favorable for recovery rather than ongoing injury.
The dose-response relationship also matters. It suggests the therapeutic effect is not an artifact of the carrier alone but is linked to the amount of active kaempferol delivered to tissue. In a condition as chronic and heterogeneous as dry eye, that kind of response gradient strengthens confidence that the pharmacology is real.
What This Formulation Solves, and What It Still Cannot Answer
This work addresses a familiar failure point in ophthalmic drug development: promising compounds often have acceptable biology but poor delivery. Kaempferol has repeatedly shown anti-inflammatory and antioxidant effects in ocular models, including effects on corneal neovascularization, retinal pigment epithelial signaling, glaucomatous injury pathways, and dry eye surface damage. The barrier has been less about whether the molecule has activity and more about whether it can be delivered in a way that preserves that activity at the eye.
KAE-NIO-ISG is designed to answer that problem with a dual-platform strategy. The niosome improves solubilization and vesicular protection; the ion-sensitive gel prolongs ocular residence. The result is a system that improved corneal exposure and produced a therapeutic effect comparable to cyclosporine in mice. For a natural compound with poor aqueous solubility and photosensitivity, that is a substantial formulation advance.
What remains unresolved is clinical translation. The study was preclinical, used animal models, and does not establish human efficacy, tolerability over long-term use, or comparative benefit in broader dry eye subtypes. It also does not answer how the formulation would perform in real-world patients with variable tear chemistry, coexisting meibomian gland dysfunction, or chronic topical medication exposure. Those questions belong to later-stage development, where safety durability, dosing frequency, and human ocular pharmacokinetics will need to be measured directly.